Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 7
1996 1
1997 6
1998 6
1999 3
2000 4
2001 1
2002 3
2003 3
2004 1
2005 2
2006 3
2007 7
2008 3
2009 1
2010 6
2011 7
2012 3
2013 4
2014 7
2015 1
2016 4
2017 2
2018 7
2019 6
2020 4
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29748210

102 results

Results by year

Filters applied: . Clear all
Page 1
Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.
Marzi L, Agama K, Murai J, Difilippantonio S, James A, Peer CJ, Figg WD, Beck D, Elsayed MSA, Cushman M, Pommier Y. Marzi L, et al. Mol Cancer Ther. 2018 Aug;17(8):1694-1704. doi: 10.1158/1535-7163.MCT-18-0028. Epub 2018 May 10. Mol Cancer Ther. 2018. PMID: 29748210 Free PMC article.
NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Burton JH, Mazcko C, LeBlanc A, Covey JM, Ji J, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana S, Weishaar K, London C, Kisseberth W, Krick E, Vail D, Childress M, Bryan JN, Barber L, Ehrhart EJ, Kent M, Fan T, Kow K, Northup N, Wilson-Robles H, Tomaszewski J, Holleran JL, Muzzio M, Eiseman J, Beumer JH, Doroshow JH, Pommier Y. Burton JH, et al. Clin Cancer Res. 2018 Dec 1;24(23):5830-5840. doi: 10.1158/1078-0432.CCR-18-1498. Epub 2018 Jul 30. Clin Cancer Res. 2018. PMID: 30061364 Free PMC article.
Targeting Topoisomerase I in the Era of Precision Medicine.
Thomas A, Pommier Y. Thomas A, et al. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589. doi: 10.1158/1078-0432.CCR-19-1089. Epub 2019 Jun 21. Clin Cancer Res. 2019. PMID: 31227499 Free PMC article. Review.
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
Coussy F, El-Botty R, Château-Joubert S, Dahmani A, Montaudon E, Leboucher S, Morisset L, Painsec P, Sourd L, Huguet L, Nemati F, Servely JL, Larcher T, Vacher S, Briaux A, Reyes C, La Rosa P, Lucotte G, Popova T, Foidart P, Sounni NE, Noel A, Decaudin D, Fuhrmann L, Salomon A, Reyal F, Mueller C, Ter Brugge P, Jonkers J, Poupon MF, Stern MH, Bièche I, Pommier Y, Marangoni E. Coussy F, et al. Sci Transl Med. 2020 Feb 19;12(531):eaax2625. doi: 10.1126/scitranslmed.aax2625. Sci Transl Med. 2020. PMID: 32075943 Free PMC article.
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Jossé R, Martin SE, Guha R, Ormanoglu P, Pfister TD, Reaper PM, Barnes CS, Jones J, Charlton P, Pollard JR, Morris J, Doroshow JH, Pommier Y. Jossé R, et al. Cancer Res. 2014 Dec 1;74(23):6968-79. doi: 10.1158/0008-5472.CAN-13-3369. Epub 2014 Sep 30. Cancer Res. 2014. PMID: 25269479 Free PMC article.
102 results